Wockhardt Limited (WOCKPHARMA.NS)
INR 1319.15
(9.91%)
INR 1319.15
(9.91%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 39.87 Billion INR | -0.85% |
| 2022 | 40.21 Billion INR | -0.49% |
| 2021 | 40.41 Billion INR | 0.71% |
| 2020 | 40.12 Billion INR | -21.65% |
| 2019 | 51.21 Billion INR | 6.11% |
| 2018 | 48.26 Billion INR | -2.77% |
| 2017 | 49.64 Billion INR | -5.45% |
| 2016 | 52.5 Billion INR | 45.46% |
| 2015 | 36.09 Billion INR | 17.2% |
| 2014 | 30.79 Billion INR | 6.03% |
| 2013 | 29.04 Billion INR | -12.93% |
| 2012 | 33.35 Billion INR | -30.25% |
| 2011 | 47.82 Billion INR | 0.43% |
| 2010 | 47.62 Billion INR | -2.62% |
| 2009 | 48.9 Billion INR | -14.36% |
| 2008 | 57.1 Billion INR | 47.19% |
| 2007 | 38.79 Billion INR | 46.51% |
| 2006 | 26.47 Billion INR | 98.67% |
| 2005 | 13.32 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -36.62 Billion INR | -191.85% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 39.87 Billion INR | 0.0% |
| 2023 FY | 39.87 Billion INR | -0.85% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 39.88 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 39.97 Billion INR | 0.0% |
| 2022 FY | 40.21 Billion INR | -0.49% |
| 2022 Q4 | 40.21 Billion INR | 0.0% |
| 2021 FY | 40.41 Billion INR | 0.71% |
| 2021 Q2 | 42.17 Billion INR | 0.0% |
| 2021 Q4 | 40.41 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 40.12 Billion INR | -21.65% |
| 2020 Q2 | 46.26 Billion INR | 0.0% |
| 2020 Q4 | 40.12 Billion INR | 0.0% |
| 2019 FY | 51.21 Billion INR | 6.11% |
| 2019 Q4 | 51.21 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 49.19 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q4 | 48.26 Billion INR | 0.0% |
| 2018 FY | 48.26 Billion INR | -2.77% |
| 2018 Q2 | 50.93 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 49.64 Billion INR | -5.45% |
| 2017 Q4 | 49.64 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 50.3 Billion INR | 0.0% |
| 2016 FY | 52.5 Billion INR | 45.46% |
| 2016 Q4 | 52.5 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 50.08 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 36.09 Billion INR | 17.2% |
| 2015 Q2 | 32.3 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 36.09 Billion INR | 0.0% |
| 2014 Q2 | 28.79 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 30.79 Billion INR | 6.03% |
| 2014 Q4 | 30.79 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2013 Q2 | 33.68 Billion INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 FY | 29.04 Billion INR | -12.93% |
| 2013 Q4 | 29.04 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2012 FY | 33.35 Billion INR | -30.25% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q4 | 33.35 Billion INR | 0.0% |
| 2012 Q2 | 44.31 Billion INR | 0.0% |
| 2011 FY | 47.82 Billion INR | 0.43% |
| 2011 Q4 | 47.82 Billion INR | 0.0% |
| 2010 FY | 47.62 Billion INR | -2.62% |
| 2009 FY | 48.9 Billion INR | -14.36% |
| 2008 FY | 57.1 Billion INR | 47.19% |
| 2007 FY | 38.79 Billion INR | 46.51% |
| 2006 FY | 26.47 Billion INR | 98.67% |
| 2005 FY | 13.32 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | -144.995% |
| Hester Biosciences Limited | 3.59 Billion INR | -1009.127% |
| Aarti Drugs Limited | 11.5 Billion INR | -246.575% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -383.232% |
| Albert David Limited | 1.15 Billion INR | -3366.64% |
| Alembic Limited | 1.43 Billion INR | -2684.023% |
| Alkem Laboratories Limited | 48.6 Billion INR | 17.971% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -6012.415% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -719.078% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -13705.449% |
| Brooks Laboratories Limited | 248.6 Million INR | -15937.747% |
| Eris Lifesciences Limited | 38.26 Billion INR | -4.186% |
| FDC Limited | 3.7 Billion INR | -974.893% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -669.557% |
| Gufic Biosciences Limited | 5.59 Billion INR | -611.988% |
| Hikal Limited | 12.99 Billion INR | -206.813% |
| Ind-Swift Limited | 13.45 Billion INR | -196.366% |
| Innova Captab Limited | 4.89 Billion INR | -713.695% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -529.967% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -13335.099% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 34.932% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -3610.408% |
| Lupin Limited | 96.23 Billion INR | 58.571% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -1917.395% |
| Medico Remedies Limited | 438.24 Million INR | -8997.672% |
| Morepen Laboratories Limited | 4.45 Billion INR | -793.988% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -255.408% |
| Orchid Pharma Limited | 3.84 Billion INR | -937.18% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -1456.692% |
| RPG Life Sciences Limited | 1.38 Billion INR | -2788.712% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -6092.119% |
| Sigachi Industries Limited | 2.53 Billion INR | -1475.102% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | -182.93% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -1859.956% |
| Themis Medicare Limited | 1.88 Billion INR | -2012.306% |
| Unichem Laboratories Limited | 8.06 Billion INR | -394.098% |
| Vaishali Pharma Limited | 371.16 Million INR | -10641.911% |
| Wanbury Limited | 3.15 Billion INR | -1163.501% |
| Windlas Biotech Limited | 1.76 Billion INR | -2161.871% |
| ZIM Laboratories Limited | 2.08 Billion INR | -1816.125% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -1641.458% |
| Ipca Laboratories Limited | 33.74 Billion INR | -18.159% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 78.281% |
| Venus Remedies Limited | 1.39 Billion INR | -2762.579% |
| Sakar Healthcare Limited | 1.26 Billion INR | -3056.07% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 73.805% |
| Divi's Laboratories Limited | 18.99 Billion INR | -109.953% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -989.014% |
| Mankind Pharma Limited | 23.87 Billion INR | -66.997% |
| Sequent Scientific Limited | 8.27 Billion INR | -381.856% |
| Laurus Labs Limited | 42.71 Billion INR | 6.66% |
| Neuland Laboratories Limited | 5.49 Billion INR | -625.099% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -272.338% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 38.766% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 44.465% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -4986.601% |
| Bal Pharma Limited | 2.51 Billion INR | -1487.639% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 62.727% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -1790.603% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -24851.343% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | -1037.323% |
| Shilpa Medicare Limited | 12.93 Billion INR | -208.294% |
| Valiant Laboratories Limited | 1.05 Billion INR | -3667.502% |
| Ajanta Pharma Limited | 10.71 Billion INR | -272.258% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -2215.079% |
| Granules India Limited | 22.95 Billion INR | -73.692% |
| Medicamen Biotech Limited | 940.36 Million INR | -4139.834% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -3321.698% |
| Piramal Enterprises Limited | 560.47 Billion INR | 92.886% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 51.408% |
| NATCO Pharma Limited | 10.53 Billion INR | -278.561% |
| Suven Life Sciences Limited | 148.62 Million INR | -26726.626% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -1240.657% |
| Strides Pharma Science Limited | 37.68 Billion INR | -5.811% |
| Indoco Remedies Limited | 10.34 Billion INR | -285.504% |
| Alpa Laboratories Limited | 307.12 Million INR | -12881.812% |
| Lasa Supergenerics Limited | 541.92 Million INR | -7257.107% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -924.172% |